Sharechat Logo

Pacific Edge shares drop 9.4% as slow sales progress bring cash burn in focus

Tuesday 29th May 2018

Text too small?

Pacific Edge shares fell 9.4 percent after the company stayed in the red and said commercial deals in the US were taking longer than expected, raising questions about whether its cash reserves are deep enough. 

"Things seem to be moving quite slowly for the company, slower than what management thought," said Grant Williamson, director at Christchurch-based Hamilton Hindin Greene. 

Pacific Edge, which has a suite of four Cxbladder cancer diagnostics tests, had $16.2 million in cash and cash equivalents at March 31, including proceeds from the capital raise in November 2017. Pacific Edge raised $21.3 million in a deeply discounted rights issue, which it said would fund its goal to break even in the 2019 financial year. Its operational cash outflow widened to $18.1 million from $17.8 million. 

"Cash is going to be a concern in several months time ... they need to generate more sales in order to reduce their cash burn which unfortunately, because of these slow negotiations, hasn't eventuated at this stage." 

The shares dropped 3 cents to 29 cents and have fallen 18 percent so far this year. 

The Dunedin-based company reported a loss of $19.7 million in the year to March 31, or 4.5 cents per share, versus a loss of $22.6 million in the prior year, or 5.7 cents per share, after the prior year was restated in line with the NZ IFRS 15 revenue accounting standards. 

Pacific Edge said while it has progressed commercial negotiations with targeted large-scale healthcare organisations in the US over the past 12 months, including Kaiser Permanente and the Centers for Medicare and Medicaid, both are taking longer than expected to complete.

"Pacific Edge has little to no control over the decision making processes and timings of these large organisations," it said. 

"The multi-billion dollar US healthcare market remains our most significant opportunity and we are seeking to position Cxbladder as the preferred diagnostic test of choice for physicians in a market that offers more than 5 million potential test opportunities per annum," said chair Chris Gallaher. 


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Spark scolded for misleading customers on broadband price hike
Zespri annual profit jumps 77% on higher kiwifruit sales, increased licensing
Freightways says express package growth slowed in 2H, may flow into FY2020
BUDGET 2019: NZ debt target to be more flexible from 2022
Argosy annual profit climbs 36% on revaluation gains, pays slightly bigger dividend
NZ-owned banks says RBNZ capital proposals will make it harder to compete
Sanford earnings hit by vessel impact from crew death
Metroglass' Australian woes drag annual net profit down 69%
Fonterra says more assets under review as it cuts guidance, narrows forecast payout
Active, planning role urged for new infrastructure body

IRG See IRG research reports